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IMMUNOPATHOLOGY AND INFECTIOUS DISEASES
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J. Jason Collier, Ph.D., Pen-
nington Biomedical Research
Center, 6400 Perkins Rd, Baton
Rouge, LA 70808. E-mail:
jason.collier@pbrc.edu.
Steroid-induced diabetes is the most common form of drug-induced hyperglycemia. Therefore, meta-
bolic and immunological alterations associated with chronic oral corticosterone were investigated using
male nonobese diabetic mice. Three weeks after corticosterone delivery, there was reduced sensitivity
to insulin action measured by insulin tolerance test. Body composition measurements revealed
increased fat mass and decreased lean mass. Overt hyperglycemia (>250 mg/dL) manifested 6 weeks
after the start of glucocorticoid administration, whereas 100% of the mice receiving the vehicle control
remained normoglycemic. This phenotype was fully reversed during the washout phase and readily
reproducible across institutions. Relative to the vehicle control group, mice receiving corticosterone
had a significant enhancement in pancreatic insulin-positive area, but a marked decrease in CD3þ cell
infiltration. In addition, there were striking increases in both citrate synthase gene expression and
enzymatic activity in skeletal muscle of mice in the corticosterone group relative to vehicle control.
Moreover, glycogen synthase expression was greatly enhanced, consistent with elevations in muscle
glycogen storage in mice receiving corticosterone. Corticosterone-induced hyperglycemia, insulin
resistance, and changes in muscle gene expression were all reversed by the end of the washout phase,
indicating that the metabolic alterations were not permanent. Thus, male nonobese diabetic mice allow
for translational studies on the metabolic and immunological consequences of glucocorticoid-
associated interventions in a mouse model with genetic susceptibility to autoimmune disease.
(Am J Pathol 2017, 187: 614e626; http://dx.doi.org/10.1016/j.ajpath.2016.11.009)
Type 1 diabetes mellitus (T1D) is an organ-specific auto-
immune disease that manifests when circulating insulin
levels are reduced because of damaged and dysfunctional
pancreatic islet b-cells.1 Although no single trigger has
emerged to directly explain the targeted assault on pancre-
atic islet b-cells by the host immune system leading to T1D,
there are a variety of postulated causes for the increasing
incidence of disease.2e5 It is well established that innate and
adaptive immune pathways are key contributors to the
decrements in islet b-cell mass and function.6e9 Proin-
flammatory cytokines secreted from leukocytes initiate
specific signaling cascades, which coordinately alter islet
b-cell transcriptional responses.10,11 One major outcome of
this genetic reprogramming is the production and release of
chemotactic molecules, which regulate leukocytic infiltra-
tion into pancreatic tissue.11,12 In addition, the proin-
flammatory cytokines IL-1b and interferon-g also reduce
Supported in part by NIH grants P20-GM103528 (J.J.C.) and R01-
DK103860 (R.C.N.); and in part by a Physicians’ Medical Education and
Research Foundation (Knoxville, TN) grant (J.J.C. and M.D.K.). This
project also used resources provided by the LA CaTS (NIH U54-
GM104940) center grant and the Pennington Biomedical Research Center
Genomics and the Cell Biology and Bioimaging Core Facilities, which
are supported in part by COBRE (NIH P20-GM103528) and NORC (NIH
P30-DK072476) NIH center grants.
Disclosures: None declared.
Copyright ª 2017 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ajpath.2016.11.009
ajp.amjpathol.org
The American Journal of Pathology, Vol. 187, No. 3, March 2017
insulin secretion, proliferation, and viability through direct
actions on b-cells.12e16 Thus, strategies to eliminate or
reduce inflammation in pancreatic islets may be ideal
approaches for therapeutic intervention to treat autoimmune
forms of diabetes.
Glucocorticoids are a major class of lipophilic molecules
with powerful anti-inflammatory effects. Endogenously
produced glucocorticoids are important steroidal hormones
that regulate immune responses, adipocyte differentiation,
neurological outcomes, and metabolic homeostasis.17 The
clinically beneficial impact of glucocorticoids has been
recognized for decades and is still used to treat a variety
of human diseases that have inflammatory components,
including rheumatoid arthritis and inflammatory bowel
disease. In addition, early efforts showed a potentially
promising utility of glucocorticoid intervention for
T1D.18,19 However, a host of undesirable metabolic adverse
effects often limits the utility of chronic glucocorticoid-
based interventions as therapeutic options to treat specific
human diseases.20e22 One such adverse effect is insulin
resistance and the potential for onset of steroid-induced
diabetes.23e26
In this study, we used male nonobese diabetic (NOD)
mice to examine the immunological and metabolic effects
associated with chronic glucocorticoid intervention. Male
NOD mice display genetic susceptibility for T-lymphocyte
infiltration into the pancreatic tissue, but develop diabetes
at a much lower frequency than female NOD mice. This
reduced incidence of disease makes the male NOD mouse
an excellent model in which to investigate specific mech-
anisms that adversely affect metabolic homeostasis (eg,
insulin resistance) while also permitting concomitant
evaluation of variables that influence the course of auto-
immune disease (eg, immune cell infiltration). Herein, we
show that male NOD mice become hyperglycemic after 5
to 6 weeks of oral corticosterone exposure. Changes in
insulin sensitivity are apparent before overt hyperglycemia
and are completely reversible on removal of the steroid.
Major changes in body composition, notably a decrease in
lean body mass concomitant with increases in fat mass, are
consistent with our observations of insulin resistance and
hyperglycemia. On a positive note, corticosterone reduces
infiltration of CD3þ cells into the pancreatic tissue, a
phenotype that remains stable after discontinuation of
steroid administration. Collectively, our results indicate
that male NOD mice are a useful preclinical model system
in which to investigate both metabolic and immuno-




Male NOD mice were acquired from the Jackson Labora-
tories (Bar Harbor, ME). Mice between 9 and 11 weeks
of age were group housed and allowed to acclimate to the
photoperiod (12-hour light/12-hour dark) and temperature
conditions (22C  1C) of each animal facility for 7 days.
This 1-week acclimation period was standard procedure on
animal arrival at each participating institution. During
studies at both sites [University of Tennessee (Knoxville,
TN) and Pennington Biomedical Research Center (Baton
Rouge, LA)], mice were fed Harlan Teklad Diet 8640
(Envigo, Madison, WI) and given access to tap water ad
libitum. Randomization into experimental groups was made
using fasting blood glucose levels and body weights to
ensure these metabolic variables were similar at the onset of
the intervention. A baseline blood glucose value was ob-
tained from the tail vein immediately before beginning the
drinking water interventions. Corticosterone (27840) was
purchased from Sigma-Aldrich (St. Louis, MO) and
administered in 1% ethanol drinking water at 100 mg/mL.
Briefly, corticosterone was dissolved in ethanol (E7023;
Sigma) and diluted with water to make a 1% ethanol so-
lution. Animals in the vehicle control groups received a 1%
ethanol drinking water solution. Water was changed every
3 to 4 days. Blood glucose levels and body weights were
measured once a week throughout the study. Six weeks
after corticosterone dosing, mice were taken off of the
steroid (and corresponding ethanol vehicle) and switched to
standard drinking water for the remainder of the study
(denoted as washout phase below). After in vivo measure-
ments were complete, animals were euthanized via carbon
dioxide asphyxiation and trunk blood was collected for
serum after decapitation. Fat depots, skeletal muscle, and
liver were snap frozen in liquid nitrogen for long-term
storage at 80C, whereas pancreata were fixed in 10%
neutral-buffered formalin (Sigma) for histological and
immunohistochemical analyses. Time-domain nuclear
magnetic resonance to measure body composition was
performed at Pennington Biomedical Research Center. The
ex vivo analyses were also performed at Pennington
Biomedical Research Center. All procedures were approved
by each respective Institutional Animal Care and Use
Committee at the University of Tennessee and Pennington
Biomedical Research Center.
Insulin Tolerance Test
At the beginning of the fourth week of the study (3 weeks
after initiating the corticosterone regimen), an insulin
tolerance test was performed essentially as described.27
Briefly, Humulin R insulin (Lilly, Indianapolis, IN) was
administered at 0.75 U/kg body weight via i.p. injection
following a 2-hour fast. Blood samples were taken from the
tail vein immediately before the injection, as well as at 15,
30, 60, 90, and 120 minutes after injection. Blood glucose
was read with an ACCU-CHEK Aviva PLUS Glucometer
(Roche Diagnostics, Indianapolis, IN). Blood glucose levels
were plotted against time, and the area under the curve was
calculated.
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Islet Histology and Measurements of Serum Insulin
Our procedures for sectioning, embedding, and measuring
insulin-positive area and CD3þ cell infiltration have been
described.28 Serum insulin was measured using the Ultra-
sensitive Mouse Insulin enzyme-linked immunosorbent
assay kit (catalog number 10-1249-01) from Mercodia
(Uppsala, Sweden), according to their recommended pro-
tocol. The IBA1 antibody (catalog number 019-19741) was
from Wako (Richmond, VA). Rather than scoring pancre-
atic insulitis in a binary format, we used the following
classification scheme to allow for a semiquantitative
analysis: 0 indicates no visible infiltration; 1, visible peri-
insulitis with <10% of islet occluded; 2, visible peri-
insulitis completely encircling the islet but affecting less
than half of the islet area; 3, invasive insulitis, defined as
comprising 50% or more of the islet area being occluded
with leukocytic infiltration. Two investigators (D.H.B. and
J.J.C.), blinded to the conditions, scored the pancreatic
sections. This histology score, given as fractional degree,
was calculated by dividing the sum of all individual islet
scores by the total number of islets evaluated. For the
analysis, two pancreatic sections from each mouse were cut
approximately 150 mm apart. For each group, between 100
and 350 islets were scored. Each of these values was
plotted as a fraction of the total islets counted.
Cell Culture, Luciferase Assays, and Enzyme-Linked
Immunosorbent Assay
Culture and passage of the 832/13 rat insulinoma cell line has
been described.29 Transient transfection of plasmid vectors
into 832/13 cells, luciferase activity measurements, and che-
mokine ligand (CCL) 2 and CCL20 enzyme-linked immu-
nosorbent assays were performed as described previously.30
Total RNA Extraction, cDNA Synthesis, and Real-Time
RT-PCR
Total RNA was isolated from 832/13 cells using TRI-
Reagent solution (Thermo Fisher Scientific, Waltham, MA)
and from skeletal muscle using an RNeasy Mini Kit (Qiagen,
Hilden, Germany). The rRNA integrity was assessed by 1%
agarose gel. Total RNA was reverse transcribed into cDNA
using the iScript cDNA Synthesis kit (Bio-Rad, Hercules,
CA). Abundance of specific mRNA transcripts was
measured by real-time RT-PCR using a Carbohydrate
Metabolism PrimePCR plate (Bio-Rad) and iTaq Universal
SYBR Green Supermix (Bio-Rad). The mRNA integrity for
each cDNA sample was assessed by the RNA Quality Assay
(Bio-Rad), which has been described31 (Table 1).
Tissue Protein Isolation and Immunoblotting
Isolated rectus muscle (30 mg) tissue was homogenized in
300 mL T-PER lysis reagent (Thermo Fisher Scientific)
supplemented with Halt Protease/Phosphatase Inhibitor
Cocktail (Thermo Fisher Scientific). The protein concen-
tration of the lysate was determined using the bicinchoninic
acid assay (Thermo Fisher Scientific). Samples were heat
denatured, separated on NuPAGE Novex 4% to 12% Bis-
Tris gels (Thermo Fisher Scientific), transferred to a poly-
vinylidene difluoride membrane, blocked for 15 minutes in
Membrane Blocking Solution (Invitrogen, Carlsbad, CA),
and incubated in primary antibody overnight with rotation at
4C. The primary antibody was removed, and membranes
were washed in tris-buffered saline three times for 5 minutes
each time. Membranes were incubated with secondary
antibody for 2 hours at room temperature with rotation.
Secondary antibody was removed, and membranes were
washed in tris-buffered saline three times for 5 minutes
each time. Chemiluminescence detection was performed
using a ChemiDoc Imaging system (Bio-Rad). Antibodies
were from Abcam (Cambridge, UK; Total OXPHOS
catalog number ab110413) and Cell Signaling Technology
(Danvers, MA; b-actin catalog number 8457).
Citrate Synthase Activity, Glycogen Assays, and
Statistical Analysis
Glycogen levels were determined from 10 mg of powdered
skeletal muscle tissue using the Glycogen Assay kit
(Abcam), according to the manufacturer’s protocol. Total
glycogen content was normalized to total tissue protein. For
citrate synthase activity, 10 mg of skeletal muscle tissue was
lysed in CelLytic MT Cell Lysis Reagent (Sigma), and
enzymatic activity was determined using the Citrate Syn-
thase Assay kit (Sigma), per the manufacturer’s guidelines.
One-way analysis of variance and t-tests were performed
using GraphPad Prism software version 6.0 (GraphPad
Software, Inc., La Jolla, CA). Specific P values are given in
the individual figure legends.
Table 1 Primers Designed Using Primer3Plus Software (Cambridge, MA)




Primers for Map1lc3a/LC3 (Mm00458725_g1), MURF1/Trim63 (Mm01185221_m1), and ubiquitin B (Mm01622233_g1) were purchased from Applied Biosystems
(Foster City, CA). All other genes were measured using the Carbohydrate Metabolism PrimePCR plate run on the CFX96 real-time system (Bio-Rad, Hercules, CA).
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Results
Corticosterone Induces Hyperglycemia in Male NOD
Mice, Which Is Reversible on Steroid Removal
This study was designed to investigate the metabolic impact
of oral corticosterone delivery in male NOD mice and was
conducted at two distinct academic research sites. The two-
site approach allowed us to determine the reproducibility of
the whole body phenotype across institutions and with
distinct investigators. Oral administration of corticosterone
has the benefit of reduced handling of animals, therefore
eliminating the repeated stress of multiple injections.32
Delivery of 100 mg/mL corticosterone occurred via the
water supply for 6 weeks, followed by steroid removal (ie, a
washout phase) where all mice were given normal drinking
water instead of either the ethanol vehicle or corticosterone
(Figure 1). The blood glucose results at each site were
similar, with significant increases in glucose 5 weeks after
beginning the corticosterone regimen (Figure 1, A and B).
The combined results from each site are given in Figure 1C.
Body weights were also similar between groups at each
experimental location (Figure 1, D and E), with the col-
lective data given in Figure 1F. Thus, corticosterone-
induced hyperglycemia, and the subsequent return to
normal glucose levels after steroid withdrawal, is clearly
a reproducible phenotype across different academic in-
stitutions, conducted by separate investigators using a
standardized protocol.
Corticosterone Reduces Insulin Sensitivity in Male NOD
Mice, a Reversible Phenotype after Removal of Steroid
The onset of hyperglycemia in response to corticosterone
took 5 weeks to develop and was completely reversible on
removal of the steroid (Figure 1, AeC). Three weeks after
beginning the oral corticosterone regimen, insulin sensi-
tivity was measured by insulin tolerance test (outline of
experimental intervention given in Figure 2A). There is a
clear ability of insulin to lower blood glucose levels in the
vehicle control group (Figure 2B), indicating a normal
response to hormone injection. By contrast, this response is
markedly blunted in the mice receiving corticosterone
(Figure 2B). The area under the curve shows a 22% dif-
ference in mice receiving corticosterone relative to the mice
receiving the vehicle control (Figure 2C). Interestingly,
4 weeks after removal of corticosterone (and vehicle),
Figure 1 Corticosterone induces hyperglycemia in male NOD mice. Blood glucose (AeC) and body weights (DeF) were measured weekly during both
delivery and washout phases. Lines indicate the timeline of vehicle and corticosterone administration. Site 1 indicates Pennington Biomedical Research
Center; site 2, University of Tennessee; and the combined graph, the sum of data collected at each site. Data are shown as means  SEM. n Z 8 per group
(A, B, D, and E); n Z 16 (C and F). *P < 0.05, **P < 0.01, and ***P < 0.001. Tx, treatment.
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insulin sensitivity in the mice previously receiving cortico-
sterone returned to normal (Figure 2D). Using the area
under the curve calculation, there was a 10% improvement
in the corticosterone group over the vehicle control group,
indicating that the mice formerly receiving corticosterone
completely recovered from their insulin resistant state by the
end of the washout period (Figure 2E).
Corticosterone Stimulates Early and Sustained
Alterations in Body Composition that Are Reversible on
Steroid Withdrawal
Oral corticosterone administration promotes early and sus-
tained increases in fat mass (Figure 3A), contributing to
the overall escalation in percentage fat accumulation
(Figure 3B). By contrast, a striking decrease in lean mass
was evident 1 week after mice began the oral corticosterone
regimen (Figure 3C). The decrease in percentage lean mass
was sustained during the entire course of the corticosterone
intervention, but did not get worse over time (Figure 3D).
Fluid mass accumulated much slower (Figure 3, E and F) and
tracked most closely with onset of hyperglycemia (Figure 1,
AeC). An important observation from this study is the
complete reversal of the changes in fat and lean mass after
discontinuation of corticosterone. As shown in Figure 3, A
and B, fat mass returned to normal on withdrawal of the
glucocorticoid. Lean mass was also regained in mice once
the steroid was removed (Figure 3, C and D). Moreover, fluid
mass decreased concomitantly with the restoration of the
euglycemia during the washout phase (Figure 3, E and F).
The body composition phenotypes are also consistent with
the changes in insulin sensitivity shown in Figure 2.
Corticosterone Increases Expression of the Citrate
Synthase and Glycogen Synthase Genes, Promoting
Increases in Enzymatic Activity and Glycogen Storage,
Respectively
Using skeletal muscle, changes in several parameters
relevant to metabolic homeostasis were investigated. First,
Figure 2 Corticosterone reduces insulin sensi-
tivity in male NOD mice, which is completely
reversible after removal of steroid. A: Timeline of
vehicle and corticosterone administration [treatment
(Tx) phase] and water delivery (washout phase). In-
sulin tolerance tests (ITTs) were performed at 3 and
10 weeks, as indicated by the gray stars. BeD: Blood
glucose levels after bolus injection of insulin are
shown after 3 weeks (B) and 10 weeks (D). The area
under the curve (AUC) was calculated for ITTs per-
formed at 3 weeks (C) and 10 weeks (E). Data
are shown as means  SEM (BeE). n Z 8 per group
(BeE).*P < 0.05, **P < 0.01, and ***P < 0.001.
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we found that citrate synthase transcript abundance
was markedly up-regulated in skeletal muscle obtained
from mice given the corticosterone regimen; expression
returned to normal by the end of the washout period
(Figure 4A). Citrate synthase enzymatic activity followed
a similar pattern as the transcript levels, with elevations
during the steroid delivery period, and a return to baseline
after removal of the steroid (Figure 4B). Next, we
discovered that the gene encoding glycogen synthase was
robustly responsive in mice that had received corticoste-
rone but returned to the presteroid state by the end of the
washout period (Figure 4C). Glycogen accumulated in
skeletal muscle from corticosterone-exposed mice, a
phenotype that also reverted to normal on cessation of
steroid delivery (Figure 4D). Taken together, alterations in
skeletal muscle metabolic homeostasis during chronic
glucocorticoid administration were completely reversed on
steroid removal.
Corticosterone Promotes the Expression of Genes
Regulating Glucose Metabolism and Protein
Breakdown, Consistent with Changes in Both Insulin
Sensitivity and Decreases in Lean Body Mass
Because we observed major changes in insulin sensitivity
(Figure 2) and glycogen storage (Figure 4D), we next
measured genes directly linked with regulation of glucose
metabolism. Expression of Pdk4, which encodes the enzyme
pyruvate dehydrogenase lipoamide kinase isozyme 4
(mitochondrial), was increased nearly 40-fold in muscle
isolated from the mice given corticosterone (Figure 5A).
This is consistent with the known regulation of Pdk4 by
glucocorticoids.33 We next examined Pgk1, which encodes
the phosphoglycerate kinase, a glycolytic enzyme that
catalyzes the reaction 1,3-bisphosphoglycerate þ ADP /
3-phosphoglycerate and ATP. We found that the expression
of the Pgk1 gene was reduced by 80% in muscle isolated
from mice in the corticosterone group (Figure 5B). Similar
to observations for other genes screened in skeletal muscle,
expression of Pgk1 was restored to normal levels once the
corticosterone was removed.
Because of the reduction in insulin tolerance (Figure 2),
we investigated the expression of two genes encoding key
regulatory enzymes involved in hexosamine production, a
metabolic pathway linked with insulin resistance.34 The gene
encoding glutamine/fructose-6-phosphate amidotransferase
(Gfpt1), which is considered the rate-controlling enzyme for
hexosamine biosynthesis, was elevated 70-fold in muscle
from mice in the corticosterone group (Figure 5C). The
expression of O-linked-b-N-acetylglucosamine (O-GlcNAc)
transferase (Ogt), which produces the enzyme that catalyzes
the transfer of O-GlcNAc to serine or threonine residues of
proteins, was increased 50-fold in the muscle of mice that
had received corticosterone (Figure 5D). Expression of both
Gfpt1 and Ogt returned to normal by the end of the steroid
washout period (Figure 5, C and D).
We queried the expression of several ubiquitin ligases as
a starting point to explain the significant loss in lean body
mass in corticosterone-treated mice (Figure 3, C and D).
Figure 3 Corticosterone stimulates early and sustained alterations in body composition that are reversible on steroid withdrawal. The solid black bar
indicates the timeline of vehicle or corticosterone administration. Fat (A), lean (C), and fluid (E) masses were determined weekly by nuclear magnetic
resonance spectroscopy. Fat (B), lean (D) and fluid (F) masses were also calculated as a percentage of body weight. Data are shown as means  SEM. nZ 8 per
group. *P < 0.05, **P < 0.01, and ***P < 0.001.
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MuRF1, an E3 ubiquitin ligase, was expressed 20-fold
higher in muscle from corticosterone-exposed mice rela-
tive to vehicle control mice (Figure 5E). Expression of
MuRF1 returned to normal during the washout period
(Figure 5E). In addition, the gene encoding microtubule-
associated protein 1 light chain (LC3), a key regulatory
ubiquitin-like protein associated with autophagy, was
expressed 234-fold over the vehicle control; LC3 expres-
sion also reverted to control levels by the end of the
washout phase of the study (Figure 5F). The protein
abundance of b-actin, which is decreased in other models
of skeletal muscle atrophy,35 is also diminished in
corticosterone-exposed mice (Supplemental Figure S1).
This reduced abundance returns to normal during the
washout phase (Supplemental Figure S1). Of significance,
the integrity of proteins associated with the electron
transport chain is maintained (Supplemental Figure S1),
indicating that there is selective, rather than global, protein
turnover. Therefore, the skeletal muscle gene expression
patterns are consistent with observations of insulin resis-
tance and skeletal muscle wasting shown in Figures 2 and 3
and also with alterations in transcript abundance put forth
in Figure 5, E and F.
Corticosterone Enhances Pancreatic Islet
Insulin-Positive Area and Islet Fraction, and Is
Associated with Marked Increases in Circulating
Insulin
Because pancreatic islets expand during states of insulin
resistance,21 we measured insulin-positive cell area,
indicative of the pancreatic b-cell population, in response to
the corticosterone intervention. Insulin-positive area
increased by 2.1-fold in corticosterone-treated mice
(Figure 6, A and B). Moreover, there was a marked
enhancement in the islet fraction (Figure 6C), a measure of
the insulin-positive cell area relative to total pancreatic area.
Taken together, these results are consistent with islet b-cell
mass expansion. However, there was no statistically sig-
nificant increase in either the number of islets per section
(Figure 6D) or the glucagon-positive cell area (data not
shown). However, circulating insulin was >25-fold higher
in the corticosterone group when compared with the vehicle
control group; this marked elevation in serum insulin
completely returned to normal by the end of the washout
phase of the study (Figure 6E).
CD3þ Cell Infiltration Decreases during Corticosterone
Intervention and Remained Stable on Steroid
Withdrawal
NOD mice inherently display markedly high levels of
lymphocytic infiltration, a key feature of the decrease in islet
b-cell mass that leads to diabetes.28,36 The extent of insulitis
in the vehicle versus corticosterone groups was examined by
histological analysis and given in Figure 7A. We note that
2.7-fold more islets in the corticosterone group were
completely free of any visible immune cell association
(Figure 7A). By contrast, 8.9-fold more islets in the vehicle
group displayed the highest insulitis score possible, indi-
cating a much higher fraction of islet tissue was invasively
infiltrated (Figure 7A). After steroid washout, 4.1-fold more
Figure 4 Corticosterone (Cort) increases expression of the citrate synthase and glycogen
synthase genes, promoting increases in enzymatic activity and glycogen storage, respectively.
Citrate synthase (Cs) gene expression (A), citrate synthase activity (B), glycogen synthase (Gys1)
gene expression (C), and glycogen levels (D) were measured in rectus muscle from male NOD mice
after both delivery and washout phases. Data are shown as means  SEM. n Z 5 per group.
*P < 0.05, **P < 0.01, and ***P < 0.001. Veh, vehicle.
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islets in the corticosterone group retained a score of 0,
indicating they were still free of visible immune cell infil-
tration (Figure 7B). Moreover, we observed that 1.7-fold
more islets in the vehicle group received a score of 3 at
the conclusion of the washout period, indicting invasive
insulitis was more severe in these mice when compared with
their counterparts in the corticosterone group (Figure 7B).
We next stained for CD3þ cells as an indicator of
T-lymphocyte entry into the pancreatic tissue. This immu-
nohistological analysis revealed 76% of islets labeling
positive for CD3 in the vehicle-treated mice (Figure 7C). By
contrast, only 44% of islets were positive in the cortico-
sterone group, with most islets completely free of CD3þ
immunoreactivity (Figure 7C). These results are congruent
with immunosuppressive activity of chronic glucocorticoid
administration. After the washout phase, 80% of the islets
in the vehicle group displayed CD3þ cell infiltration
(Figure 7D). However, only 56% of the islets in the corti-
costerone group were positive for T lymphocytes. We also
noticed a reduction in active macrophages during cortico-
sterone administration (Supplemental Figure S2), which was
also apparent after the washout was complete (Supplemental
Figure S3).
To explain the corticosterone-mediated decrease in T
lymphocytes (marked by CD3) and active macrophages
(marked by IBA1), we investigated the direct actions of the
steroid on cultured rat b-cells. We found that corticosterone
promoted robust glucocorticoid receptor activation
(Supplemental Figure S4A). The map kinase phosphatase 1
(alias DUSP1) was also rapidly induced by corticosterone,
a phenotype reproduced by the synthetic glucocorticoid
dexamethasone (Supplemental Figure S4B). In addition,
the IL-1bemediated expression of the chemokine CCL2
was decreased by cellular exposure to corticosterone
(Supplemental Figure S4C). CCL2 secretion was also
reduced in the presence of the steroid (Supplemental
Figure S4D). The CCL20 gene is even more strikingly
up-regulated by IL-1b, with marked reductions in this
response when corticosterone is present (Supplemental
Figure S4E). Secretion of CCL20 is also significantly
diminished by corticosterone (Supplemental Figure S4F).
Taken together, the decrease in chemokine production from
pancreatic b-cells is consistent with a reduction in the
number of islets infiltrated by host immune cells.
Discussion
Prevention and reversal of T1D are major goals of both
basic and clinical research endeavors. A variety of strategies
targeting inflammatory responses have revealed key roles
Figure 5 Corticosterone (Cort) promotes the expression of genes regulating glucose metabolism and protein breakdown, consistent with changes in both
insulin sensitivity and decreases in lean body mass. Relative Pdk4 (A), Pgk1 (B), Gfpt1 (C), Ogt (D), MuRF1 (E), and LC3 (F) mRNA abundance was determined in
rectus muscle from male NOD mice after both delivery and washout phases. Data are shown as means  SEM. n Z 5 per group. *P < 0.05, **P < 0.01. Veh,
vehicle.
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for specific signaling pathways that participate in the disease
course.7,37e39 Therefore, understanding the mechanisms
associated with anti-inflammatory approaches, such as
glucocorticoid receptor activation, offers much promise for
controlling diseases with autoimmune and autoinflammatory
components. Because the therapeutic use of glucocorticoids
is often associated with adverse metabolic phenotypes,
including steroid-induced hyperglycemia,23,40,41 separating
metabolic effects from immunological outcomes requires
further investigation. In addition, chronic stress responses,
including elevations in circulating glucocorticoids, correlate
significantly with insulin resistance, glucose intolerance,
and blood glucose levels in humans.42 Therefore, we used
the male NOD mouse to investigate specific metabolic and
immunological parameters associated with chronic oral
administration of glucocorticoid.
Using the insulin tolerance test, we found that the ability
of injected insulin to lower blood glucose levels was vastly
reduced in mice receiving corticosterone. This decrease in
insulin action occurred before the onset of overt hypergly-
cemia (Figures 1 and 2). These results can be explained in
part by the striking changes in body composition. Cortico-
sterone administration resulted in marked elevations in fat
mass, with concomitant decreases in lean mass (Figure 3).
The reciprocal alterations in body composition induced
by oral corticosterone delivery are consistent with the
development of insulin resistance (Figure 8). In addition, on
steroid withdrawal, the changes in body composition were
reversed (ie, fat mass decreased and lean mass increased)
with corresponding improvements in whole body insulin
sensitivity (Figure 2). These findings are consistent with
observations in human subjects exposed to
Figure 6 Corticosterone (Cort) enhances
pancreatic islet insulin-positive area and is asso-
ciated with marked increases in circulating insulin.
Male NOD mice received either vehicle (Veh) or
corticosterone (100 mg/mL) for 6 weeks, followed
by steroid withdrawal (washout). Pancreatic islet
insulin-positive area was evaluated by immuno-
histochemical analysis. A: The larger pancreatic
islets in the glucocorticoid-treated mice. Insulin-
positive area (B), islet fraction (C), and islet per
section (D) were quantified using five mice per
group. E: Serum insulin was measured by enzyme-
linked immunosorbent assay with eight mice per
group. Data are shown as means  SEM (BeE).
**P < 0.01, ****P < 0.0001. Scale barZ 100 mm
(A). Original magnification, 40 (A).
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glucocorticoids22,43 and with recent opinion on nuclear
hormone receptor control of insulin resistance.44
Because skeletal muscle mass contributes significantly to
whole body glucose utilization, we examined a variety of
genes associated with glucose metabolism and tissue atro-
phy. Pdk4, a known glucocorticoid responsive gene, was
markedly elevated in the corticosterone group (Figure 5A).
The increased expression of Pdk4 suggests a decrease in
glucose oxidation, thereby promoting enhanced glucose
storage as glycogen. This was confirmed by analysis of
muscle glycogen content (Figure 4D). Also, glycogen syn-
thase is up-regulated during nutrient deprivation and in-
teracts with LC3 at the autophagosome to increase glycogen
degradation (glycogen autophagy) as an energy source. This
may help to explain why the expression of glycogen syn-
thase is markedly elevated relative to the amount of
glycogen detected in skeletal muscle (Figure 4, A and B). In
addition, genes encoding key enzymes involved in hexos-
amine biosynthesis (Gfpt1) and transfer of associated sub-
strates (Ogt) were also elevated during corticosterone
administration, but returned to normal levels after the
washout period (Figure 5). These results are congruent with
earlier transgenic mouse and glucosamine infusion studies
showing that elevations in hexosamine levels promote in-
sulin resistance45,46 and further suggest that glucocorticoid-
mediated reductions in insulin sensitivity may be associated
with increases in cellular hexosamine production.
We also observed increases in the expression of MuRF1
and LC3, genes involved in ubiquitin-mediated protein
degradation and autophagy, respectively (Figure 5, E and
Figure 7 Corticosterone reduces total insulitis and CD3þ cell infiltration. Male NOD mice were given corticosterone or ethanol vehicle in the drinking water
for 6 weeks, followed by a 1-month washout period. A: Insulitis was quantified at the end of the 6-week steroid delivery arm of the study. B: The insulitis score
was determined after the 1-month washout phase. Photomicrographs of CD3þ staining in pancreatic tissue at the end of the 6-week glucocorticoid inter-
vention (C) and 1 month after the steroid removal (D). Islets of similar size were chosen for comparison. The bar graphs in C and D show quantification of islets
from four to eight mice per group. *P < 0.05, **P < 0.01. Scale bar Z 50 mm (C and D). Original magnification, 40 (C and D).
Figure 8 Glucocorticoids display robust immunomodulatory actions, but
promote changes in body composition that correlate with insulin resistance,
hyperinsulinemia, and eventual onset of hyperglycemia. Oral glucocorticoid
delivery reduces leukocytic infiltration into pancreatic tissue. However,
chronic administration of the steroid increases total fat mass, reduces whole
body lean mass, and promotes insulin resistance. Insulin resistance is linked
to hyperinsulinemia and increases in islet b-cell mass, whereas elevations in
circulating insulin are reported to suppress insulitis (see Discussion for
details and accompanying references). Severe insulin resistance, often
coupled with b-cell dysfunction, prompts the eventual onset of hypergly-
cemia. Many of the phenotypes shown in this schematic also occur in
humans and also are reversible on cessation of steroid administration.
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F). These findings help to explain the losses in lean mass
during the course of corticosterone administration (Figure 3,
C and D). In addition to promoting skeletal muscle atrophy,
glucocorticoids also prevent protein synthesis in muscle.47
Furthermore, glucocorticoids are known to promote adipo-
genesis,48 consistent with the increases in fat mass observed
in the present study. Taken together, these data provide at
least a partial explanation for the changes in body compo-
sition observed during oral corticosterone delivery and also
after discontinuation of the steroid hormone regimen.
An interesting observation between our studies and those
conducted using C57BL/6 mice is the difference in time to
develop hyperglycemia. Appearance of elevated blood
glucose levels was reported to occur in the first week in a
study using the C57BL/6 strain,49 but is slower to develop
in the NOD mouse (Figure 1). At the present time, we do
not know why the NOD strain is more resistant to hyper-
glycemia than the C57BL/6 strain in response to oral
delivery of corticosterone. The most likely explanation is
that NOD mice are less prone to insulin resistance induced
by glucocorticoids than are mice on the C57BL/6 back-
ground. This interpretation is consistent with recent studies
showing that the NOD strain is less sensitive to high-fat
dieteinduced weight gain and associated insulin resistance
when compared with C57BL/6 mice.50 Moreover, the
observed distinctions in separate strains of mice parallel
observations reported in human studies, with African-
American individuals displaying enhanced sensitivity to
dexamethasone when compared with white Americans.51
Polymorphisms that alter expression of the glucocorticoid
receptor gene or responses to corticosteroid ligands could
also influence the severity of metabolic outcomes.52
We further found that corticosterone activates the
glucocorticoid receptor and suppresses chemokine pro-
duction from cultured b-cells (Supplemental Figure S4).
Chemokines (ie, chemotactic cytokines) are responsible for
recruiting particular populations of immune cells through
activation of their specific cell surface receptors.53 Thus,
one potential approach to reduce immune cell infiltration
into the pancreatic islets is to reduce the synthesis and
secretion of chemoattractant molecules, such as CCL2
and CCL20. These two chemokines recruit macrophages
and T lymphocytes,11,54e56 which are leukocytes impli-
cated in b-cell death during development of T1D.57 Ther-
apeutic benefit, including reduced insulitis, is achieved
after injection of a synthetic p38 mitogen-activated protein
kinase inhibitor into NOD mice.58 Our results showing
up-regulation of map kinase phosphatase 1 in b-cells59
(Supplemental Figure S4B), which restricts signaling
through the p38 mitogen-activated protein kinase
pathway,59 are consistent with the observed reduction in
insulitis after corticosterone delivery (Figure 7 and
Supplemental Figure S4). Our findings thus suggest a
prospective mechanism for reduced insulitis in the current
corticosterone administration model, which is a reduction
in b-cellederived chemokine production and secretion.
Thus, down-regulation of immune cell modulatory che-
mokines is a plausible explanation for the reduced insulitis
in our current study. Additional anti-inflammatory actions
of glucocorticoid receptor activation are also postulated to
be part of the immunomodulatory component of the
corticosterone phenotype.
The establishment and characterization of diverse mouse
models of glucocorticoid delivery provide unique opportu-
nities in which to investigate the effects of novel gluco-
corticoid receptor agonist molecules. For example, the
use of azaxanthene,60 arylindazole,61 mercaptosteroid,62 or
other molecules designed to target inflammation, could
potentially be novel therapeutic interventions for autoim-
mune and autoinflammatory diseases, including T1D. Our
observations showing that corticosterone has lasting effects
on insulitis 4 weeks after withdrawal (Figure 7) are analo-
gous to the reported effects of prednisone in human T1D
studies.18,19 Indeed, in human subjects with new-onset T1D
who received 8 weeks of prednisone treatment, antibodies
against insulin were significantly reduced months after ste-
roid withdrawal.18 Thus, it is entirely conceivable that
activation of the glucocorticoid receptor has long-lasting
immunomodulatory and immunogenetic effects that have
been underappreciated and warrant further investigation.
On a final note, the hyperinsulinemia induced by gluco-
corticoids (Figure 6E) may also have been a factor in con-
trolling the degree of insulitis in our study (Figure 8). This
idea is consistent with observations put forth in previous
work, where aggressive insulin therapy reduced insulitis and
vastly decreased the onset of autoimmune diabetes in NOD
mice.63 Similar experiments conducted using the BB rat,
another rodent model of diabetes because of autoimmune
destruction of islet b-cells, also revealed protective effects
of exogenously administered insulin.64 Therefore, it is
conceivable that a combination therapy, involving insulin, a
novel synthetic glucocorticoid receptor modulating com-
pound, or both strategies might be beneficial as direct or
adjuvant therapeutic considerations in the quest to prevent
and treat T1D. Future studies will be designed to test such
possibilities.
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